Other Balance Sheet Components - Accrued Liabilities (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Manufacturing	$ 400,000,000	$ 227,000,000
Clinical trials	319,000,000	283,000,000
Raw materials	316,000,000	260,000,000
Loss on future firm purchase commitments	268,000,000	0	$ 0
Other external goods and services	264,000,000	79,000,000
Royalties	203,000,000	241,000,000
Compensation-related	190,000,000	126,000,000
Development operations	88,000,000	137,000,000
Other	53,000,000	119,000,000
Accrued liabilities	$ 2,101,000,000	$ 1,472,000,000